Pharsight

Teva Branded Pharm patents expiration

1. Austedo patents expiration

AUSTEDO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524733 TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Apr, 2031

(6 years from now)

US9550780 TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524733

(Pediatric)

TEVA BRANDED PHARM Benzoquinoline inhibitors of vesicular monoamine transporter 2
Oct, 2031

(7 years from now)

US9233959 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

US11666566 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

US9814708 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

US9296739 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(9 years from now)

US11666566

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US9233959

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US9814708

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US9550780

(Pediatric)

TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US9296739

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(9 years from now)

US11357772 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11564917 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US10959996 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11446291 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11648244 TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Mar, 2036

(11 years from now)

US11357772

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US10959996

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11564917

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11648244

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11446291

(Pediatric)

TEVA BRANDED PHARM Methods for the treatment of abnormal involuntary movement disorders
Sep, 2036

(12 years from now)

US11813232 TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Mar, 2038

(13 years from now)

US11179386 TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Mar, 2038

(13 years from now)

US11179386

(Pediatric)

TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Sep, 2038

(14 years from now)

US11813232

(Pediatric)

TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Sep, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-134) Apr 03, 2024
M(M-54) Jun 24, 2024
Pediatric Exclusivity(PED) Dec 24, 2024
New Indication(I-751) Aug 30, 2020
New Chemical Entity Exclusivity(NCE) Apr 03, 2022
Orphan Drug Exclusivity(ODE) Apr 03, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: 25 December, 2023

Market Authorisation Date: 03 April, 2017

Treatment: A method of treating huntington's chorea; Treatment of tardive dyskinesia

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage

AUSTEDO family patents

Family Patents

2. Loestrin 24 Fe patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5552394 TEVA BRANDED PHARM Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
Jul, 2014

(9 years ago)

Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient

Market Authorisation Date: 17 February, 2006

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

How can I launch a generic of LOESTRIN 24 FE before it's drug patent expiration?
More Information on Dosage

LOESTRIN 24 FE family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Loseasonique patents expiration

LOSEASONIQUE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615545 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Jun, 2023

(11 months ago)

US7858605 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Jun, 2023

(11 months ago)

US7855190 TEVA BRANDED PHARM Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
Dec, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 24, 2011

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 24 October, 2008

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

How can I launch a generic of LOSEASONIQUE before it's drug patent expiration?
More Information on Dosage

LOSEASONIQUE family patents

Family Patents

4. Norethindrone And Ethinyl Estradiol And Ferrous Fumarate patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5552394 TEVA BRANDED PHARM Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
Jul, 2014

(9 years ago)

US6667050 TEVA BRANDED PHARM Chewable oral contraceptive
Apr, 2019

(5 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 22, 2013

Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ingredient

Market Authorisation Date: 22 December, 2010

Treatment: Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE family patents

Family Patents

5. Preven Emergency Contraceptive Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6156742 TEVA BRANDED PHARM Emergency contraceptive kit
Dec, 2020

(3 years ago)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 01 September, 1998

Treatment: Kit adapted and designed to provide both data on the current reproductive status of a patient and contraception for those who are not pregnant, but recently engaged in unprotected sex

Dosage: TABLET;ORAL

More Information on Dosage

PREVEN EMERGENCY CONTRACEPTIVE KIT family patents

Family Patents

6. Proair Digihaler patents expiration

PROAIR DIGIHALER's oppositions filed in EPO
PROAIR DIGIHALER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6748947 TEVA BRANDED PHARM De-agglomerator for breath-actuated dry powder inhaler
Jun, 2021

(2 years ago)

US6701917 TEVA BRANDED PHARM Dose counter for medicament inhaler
Jun, 2021

(2 years ago)

US6871646 TEVA BRANDED PHARM De-agglomerator for breath-actuated dry powder inhaler
Jun, 2021

(2 years ago)

US8006690 TEVA BRANDED PHARM Reservoir pressure system for medicament inhaler
Jun, 2021

(2 years ago)

US6718972 TEVA BRANDED PHARM Dose metering system for medicament inhaler
Jun, 2021

(2 years ago)

US7540282 TEVA BRANDED PHARM Reservoir pressure system for medicament inhaler
May, 2023

(1 year, 24 days ago)

US9463288 TEVA BRANDED PHARM Dry powder inhalation apparatus
May, 2025

(11 months from now)

US10765820 TEVA BRANDED PHARM Dry powder inhalation apparatus
May, 2025

(11 months from now)

US8651103 TEVA BRANDED PHARM Dry powder inhalation apparatus
Mar, 2028

(3 years from now)

US10124131 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

US9731087 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(6 years from now)

US9216260 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(7 years from now)

US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

US8978966 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)

US9782550 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(11 years from now)

US9782551 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(11 years from now)

US10918816 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Dec, 2035

(11 years from now)

US10569034 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2036

(12 years from now)

US11351317 TEVA BRANDED PHARM Drug delivery device with electronics
Feb, 2038

(13 years from now)

US11357935 TEVA BRANDED PHARM Drug delivery device with electronics
Sep, 2038

(14 years from now)

US11000653 TEVA BRANDED PHARM Inhaler
Dec, 2038

(14 years from now)

US11344685 TEVA BRANDED PHARM Drug delivery device with electronics
Sep, 2039

(15 years from now)

US11439777 TEVA BRANDED PHARM Drug delivery device with electronics
May, 2040

(15 years from now)

US11464923 TEVA BRANDED PHARM Inhaler system
Jun, 2040

(16 years from now)

US11173259 TEVA BRANDED PHARM Drug delivery device with electronics and power management
Jul, 2040

(16 years from now)

US11266796 TEVA BRANDED PHARM Inhalation device with integrated electronics
Feb, 2041

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 12, 2018
New Patient Population(NPP) Apr 28, 2019

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

PROAIR DIGIHALER family patents

Family Patents

7. Proair Hfa patents expiration

PROAIR HFA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5605674 TEVA BRANDED PHARM Medicinal aerosol formulations
Feb, 2014

(10 years ago)

US7566445 TEVA BRANDED PHARM Medicinal aerosols and methods of delivery thereof
Jun, 2017

(6 years ago)

US8834849 TEVA BRANDED PHARM Medicinal aerosols and methods of delivery thereof
Jun, 2017

(6 years ago)

US6446627 TEVA BRANDED PHARM Inhaler dose counter
Dec, 2017

(6 years ago)

US7105152 TEVA BRANDED PHARM Suspension aerosol formulations
Sep, 2023

(8 months ago)

US8132712 TEVA BRANDED PHARM Metered-dose inhaler
Sep, 2028

(4 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

US10086156 TEVA BRANDED PHARM Dose counter for inhaler and method for counting doses
May, 2031

(6 years from now)

US10695512 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US9808587 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US11395889 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US10022509 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(6 years from now)

US9463289 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 16, 2011

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 29 October, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of PROAIR HFA before it's drug patent expiration?
More Information on Dosage

PROAIR HFA family patents

Family Patents

8. Proair Respiclick patents expiration

PROAIR RESPICLICK's oppositions filed in EPO
PROAIR RESPICLICK IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6446627 TEVA BRANDED PHARM Inhaler dose counter
Dec, 2017

(6 years ago)

US6871646 TEVA BRANDED PHARM De-agglomerator for breath-actuated dry powder inhaler
Jun, 2021

(2 years ago)

US6748947 TEVA BRANDED PHARM De-agglomerator for breath-actuated dry powder inhaler
Jun, 2021

(2 years ago)

US6718972 TEVA BRANDED PHARM Dose metering system for medicament inhaler
Jun, 2021

(2 years ago)

US8006690 TEVA BRANDED PHARM Reservoir pressure system for medicament inhaler
Jun, 2021

(2 years ago)

US6701917 TEVA BRANDED PHARM Dose counter for medicament inhaler
Jun, 2021

(2 years ago)

US7540282 TEVA BRANDED PHARM Reservoir pressure system for medicament inhaler
May, 2023

(1 year, 24 days ago)

US9463288 TEVA BRANDED PHARM Dry powder inhalation apparatus
May, 2025

(11 months from now)

US10765820 TEVA BRANDED PHARM Dry powder inhalation apparatus
May, 2025

(11 months from now)

US8651103 TEVA BRANDED PHARM Dry powder inhalation apparatus
Mar, 2028

(3 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

US10124131 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US9731087 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(6 years from now)

US9216260 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jun, 2031

(7 years from now)

US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

US8978966 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(7 years from now)

US9782550 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(11 years from now)

US9782551 TEVA BRANDED PHARM Compliance monitoring module for a breath-actuated inhaler
Aug, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 12, 2018
New Patient Population(NPP) Apr 28, 2019

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

PROAIR RESPICLICK family patents

Family Patents

9. Qnasl patents expiration

QNASL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5605674 TEVA BRANDED PHARM Medicinal aerosol formulations
Feb, 2014

(10 years ago)

US5683677 TEVA BRANDED PHARM Medicinal aerosol formulations
Nov, 2014

(9 years ago)

US5776432 TEVA BRANDED PHARM Beclomethasone solution aerosol formulations
Jul, 2015

(8 years ago)

US7780038 TEVA BRANDED PHARM Dispensing apparatus with dosage counter
Jan, 2027

(2 years from now)

US10188811 TEVA BRANDED PHARM Nasal spray device
Oct, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Dec 17, 2017
New Product(NP) Mar 23, 2015

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 17 December, 2014

Treatment: NA

Dosage: AEROSOL, METERED;NASAL

More Information on Dosage

QNASL family patents

Family Patents

10. Quartette patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450299 TEVA BRANDED PHARM Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Oct, 2025

(1 year, 4 months from now)

US8415332 TEVA BRANDED PHARM Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Mar, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 28, 2016

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 28 March, 2013

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

How can I launch a generic of QUARTETTE before it's drug patent expiration?
More Information on Dosage

QUARTETTE family patents

Family Patents

11. Qvar 40 patents expiration

QVAR 40 IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5605674 TEVA BRANDED PHARM Medicinal aerosol formulations
Feb, 2014

(10 years ago)

US5683677 TEVA BRANDED PHARM Medicinal aerosol formulations
Nov, 2014

(9 years ago)

US5776432 TEVA BRANDED PHARM Beclomethasone solution aerosol formulations
Jul, 2015

(8 years ago)

US6446627 TEVA BRANDED PHARM Inhaler dose counter
Dec, 2017

(6 years ago)

US10086156 TEVA BRANDED PHARM Dose counter for inhaler and method for counting doses
May, 2031

(6 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

US11395889 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US9463289 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

US10022509 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(6 years from now)

US9808587 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US10695512 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 15 September, 2000

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of QVAR 40 before it's drug patent expiration?
More Information on Dosage

QVAR 40 family patents

Family Patents

12. Qvar 80 patents expiration

QVAR 80 IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5605674 TEVA BRANDED PHARM Medicinal aerosol formulations
Feb, 2014

(10 years ago)

US5683677 TEVA BRANDED PHARM Medicinal aerosol formulations
Nov, 2014

(9 years ago)

US5776432 TEVA BRANDED PHARM Beclomethasone solution aerosol formulations
Jul, 2015

(8 years ago)

US6446627 TEVA BRANDED PHARM Inhaler dose counter
Dec, 2017

(6 years ago)

US10022509 TEVA BRANDED PHARM Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(6 years from now)

US9808587 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US10022510 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

US10086156 TEVA BRANDED PHARM Dose counter for inhaler and method for counting doses
May, 2031

(6 years from now)

US10695512 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US9463289 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

US11395889 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 15 September, 2000

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of QVAR 80 before it's drug patent expiration?
More Information on Dosage

QVAR 80 family patents

Family Patents

13. Seasonale patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5898032 TEVA BRANDED PHARM Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
Jun, 2017

(6 years ago)

USRE39861 TEVA BRANDED PHARM Methods of extended use oral contraception
Jun, 2017

(6 years ago)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 05 September, 2003

Treatment: Prevention of pregnancy; Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception

Dosage: TABLET;ORAL

How can I launch a generic of SEASONALE before it's drug patent expiration?
More Information on Dosage

SEASONALE family patents

Family Patents

14. Seasonique patents expiration

SEASONIQUE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615545 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Jun, 2023

(11 months ago)

US7858605 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Jun, 2023

(11 months ago)

US7320969 TEVA BRANDED PHARM Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Jan, 2024

(3 months ago)

US7855190 TEVA BRANDED PHARM Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
Dec, 2028

(4 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 25 May, 2006

Treatment: Prevention of pregnancy; Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception

Dosage: TABLET;ORAL

How can I launch a generic of SEASONIQUE before it's drug patent expiration?
More Information on Dosage

SEASONIQUE family patents

Family Patents

15. Vantrela Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572803 TEVA BRANDED PHARM Abuse resistant drug formulation
Sep, 2027

(3 years from now)

US9216176 TEVA BRANDED PHARM Abuse resistant drug formulation
Sep, 2027

(3 years from now)

US8445018 TEVA BRANDED PHARM Abuse resistant drug formulation
Jul, 2029

(5 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 17 January, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

VANTRELA ER family patents

Family Patents

16. Zecuity patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6745071 TEVA BRANDED PHARM Iontophoretic drug delivery system
Feb, 2023

(1 year, 3 months ago)

US8597272 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(2 years from now)

US7973058 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds
Apr, 2027

(2 years from now)

US8155737 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(2 years from now)

US8470853 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds
Apr, 2027

(2 years from now)

US9427578 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(2 years from now)

US9272137 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds
Sep, 2027

(3 years from now)

US8366600 TEVA BRANDED PHARM Polyamine enhanced formulations for triptan compound iontophoresis
Apr, 2029

(4 years from now)

US8983594 TEVA BRANDED PHARM Electronic control of drug delivery system
Nov, 2030

(6 years from now)

US9327114 TEVA BRANDED PHARM User-activated self-contained co-packaged iontophoretic drug delivery system
Oct, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jan 17, 2016

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 17 January, 2013

Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof; Method for treating acute migraine in adults, with ...

Dosage: SYSTEM;IONTOPHORESIS

More Information on Dosage

ZECUITY family patents

Family Patents